SEC Form 4 · accession 0001209191-16-130483
Aclaris Therapeutics, Inc. · ACRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Albert Cha
Director
Period of report
Jun 29, 2016
Accepted (ET)
Jul 1, 2016 · 4:17 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001557746
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $18.32 | Jun 29, 2016 | A | 6,632 | A | — | Jun 28, 2026 | Common Stock | 6,632 | 6,632 | D |
Explanation of responses
- F1The shares underlying this option vest in twelve equal monthly installments through June 29, 2017, subject to the reporting person's continuous service as of such vesting date.